FDA Approves Expanded Label for AZILECTî for Treatment Across All Stages of Parkinson`s Disease

(June 9, 2014) - Teva Pharmaceutical Industries Ltd. today announced the U.S. Food and Drug Administration has expanded the indication for AZILECT® (rasagiline tablets) from monotherapy and adjunct to levodopa (LD) to now include adjunct to dopamine agonists (DAs). The new indication reflects that AZILECT® can be used alone or in combination with other Parkinson’s disease (PD) medications. Read more…

Click for a printer friendly version